email article
Fewer than 40% of patients with chronic lymphocytic leukemia (CLL) had an adequate immune response to two doses of the Pfizer/BioNTech COVID-19 vaccine, a prospective study showed.
Overall, 39.5% of 167 patients with CLL had adequate antibody levels after the second vaccine dose. A matched comparison of a subgroup of patients with CLL and a group of healthy individuals showed that half of the patients with leukemia responded to the vaccine as compared with all of the healthy controls.
Vaccine response rates in the patients with CLL ranged from 79.2% for those who had a clinical remission after antileukemic therapy to 16% for patients who were vaccinated during treatment. Patients who had yet to be treated had an antibody response rate of 55.2%, reported Yair Herishanu, MD, of the Tel Aviv Sourasky Medical Center in Israel, and colleagues in
Little Benefit Seen From Federal Sepsis Tx Bundle
medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Former Vice President Mike Pence Has Pacemaker Implanted
dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
Best Life: New procedure to help with COPD patients
wmcactionnews5.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wmcactionnews5.com Daily Mail and Mail on Sunday newspapers.
Mysterious Ailment, Mysterious Relief: Vaccines Help Some Covid Long Haulers
physiciansweekly.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from physiciansweekly.com Daily Mail and Mail on Sunday newspapers.